Bizarre Patents
Pillow with retractable umbrella
A pillow assembly having a supporting assembly and a retractable umbrella assembly that is easily transportable and allows a user to support his/her head while covering their face from sunlight.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7553490 | Vaccines against O157 infection This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, ... | 06/30/2009 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7385039 | Methods and compositions for regulating imidazoline receptors The present invention relates to methods and compositions for regulating the activity of imidazoline receptors. In particular, the invention relates to pharmaceutical compositions comprising imidazoleacetic acid-ribotide (IAA-RP), imidazoleacetic acid-riboside (IAA-... | 06/10/2008 |
| 7344714 | Production of motif-specific and context-independent antibodies using peptide libraries as antigens The present invention is related to a method for producing motif-specific, context-independent antibodies which are specific to at least one modified amino acid residue in the context of variable surrounding amino acid or peptide sequences. The method is particularl... | 03/18/2008 |
| 7291606 | Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging. ... | 11/06/2007 |
| 7271154 | Antibiotic conjugates This invention features a compound of the following formula: wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibi... | 09/18/2007 |
| 7264808 | Synthetic peptide for neurological disorders The purified nerve growth factor consisting of 116 amino acids from the venom of Naja kaouthia snake was fragmented by trypsin digestion. The fragments were isolated individually by high pressure liquid chromatography (HPLC). Thus separated fragments were tested for... | 09/04/2007 |
| 7238361 | Smart drug delivery system The present invention provides prodrug and multi-prodrug complexes comprising drugs specifically bound to synthetic receptors in such a manner that active drug becomes available only in the presence of a targeted pathophysiologic receptor. Methods for preparation an... | 07/03/2007 |
| 7037669 | Assays for amphetamine and methamphetamine using stereospecific reagents Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antibodies for an amphetamine and/... | 05/02/2006 |
| 7022492 | Ecstasy haptens and immunogens Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a methylenedioxymethamphetamine. Immunogenic conjugates of Formula I ar... | 04/04/2006 |
| 7018979 | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel agonist (... | 03/28/2006 |
| 7014856 | Ganglioside-KLH conjugate vaccines plus OS-21 This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immuno... | 03/21/2006 |
| 7005132 | Prodrug compositions and drug delivery methods using synthetic receptors The present invention provides prodrug and multiprodrug complexes comprising drugs specifically bound to synthetic receptors in such a manner that active drug becomes available only in the presence of a targeted pathophysiologic receptor. Methods for preparation end... | 02/28/2006 |
| 7005453 | Use of hop acids to inhibit growth of and prevent toxic shock syndrome The present invention provides methods, products, and compositions for selectively inhibiting the growth of Staphylococcus aureus without preventing the growth of Lactobacillus species. Specifically, the present invention discloses the use of tetrahydr... | 02/28/2006 |
| 7001601 | Ganglioside-KLH conjugate vaccine plus QS-21 This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immuno... | 02/21/2006 |
| 6991911 | Assay for entactogens Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA)... | 01/31/2006 |
| 6967022 | Ganglioside-KLH conjugate vaccines plus QS-21 This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immuno... | 11/22/2005 |
| 6936259 | CAMP factor of Streptococcus uberis The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial speci... | 08/30/2005 |
| 6936253 | Ganglioside-KLH conjugate vaccines plus QS-21 This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immuno... | 08/30/2005 |
| 6932971 | Hapten-carrier conjugates and uses thereof The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including h... | 08/23/2005 |
| 6932969 | Ig fractions having immunomodulatory activity The invention concerns a method for preparing Ig fractions from human polyvalent intravenous Immunoglobulins (IV Ig) which are in particular likely to be responsible for the immunomodulatory effect observed during the treatment of certain autoimmune diseases. The in... | 08/23/2005 |
| 6916476 | Ganglioslide-KLH conjugate vaccine plus QS-21 This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immuno... | 07/12/2005 |
| 6713059 | Antibodies raised against immunogenic conjugates of gram-negative bacterial autoinducer molecules The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals t... | 03/30/2004 |
| 6706708 | Cytotoxic agents comprising taxanes and their therapeutic use A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking gro... | 03/16/2004 |
| 6699474 | Vaccine and immunserum against drugs of abuse Addictive drugs like cocaine, heroin or amphetamines are spreading in an epidemic manner in the western world and are an important factor in the spread of the acquired immune deficiency syndrome AIDS (multiple use of infected needles among drug addicts) t... | 03/02/2004 |
| 6686454 | Antibodies to specific regions of cyclosporine related compounds This invention relates to the production of polyclonal and monoclonal antibodies to specific regions of cyclosporine (CSA) and/or CSA metabolites/derivatives. The reactivity of these polyclonal and monoclonal antibodies make them particularly useful for i... | 02/03/2004 |
| 6632615 | Method for isolating a target biological material, capture phase, detecting phase and reagent containing them The invention concerns a method for isolating a target biological material contained in a sample, which consists in providing a capture phase comprising an organic molecule having at least a reactive function and at least a protein material capable of rec... | 10/14/2003 |
| 6518031 | Hapten-carrier conjugates for treating and preventing nicotine addiction Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the ... | 02/11/2003 |
| 6455047 | Methods to improve immunogenicity of antigens and specificity of antibodies A method of improving specific immune responses to small immunogens, haptens, has been developed by changing the linkage between the hapten and carrier being used for immunization. High affinity antibodies to the hapten cotinine have been produced using t... | 09/24/2002 |
| 6436931 | Cytotoxic agents comprising taxanes and their therapeutic use A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a ... | 08/20/2002 |
| 6407217 | Imidazolinone haptens and antigens and enzyme conjugates prepared therefrom The present invention provides an imidazolinone hapten having the structural formula ##STR1## Further provided are an antigen and an enzyme conjugate which are prepared from the imidazolinone hapten. The haptens, antigens and enzyme conjugates provid... | 06/18/2002 |
| 6391301 | Agent for identifying and treating metastasizing tumors The present invention relates to a novel composition for identifying and suppressing the growth of tumor cells, which comprises antibodies which react with proteins having N-glycosidically bonded saccharides.... | 05/21/2002 |
| 6350449 | Antibodies to meningococcal polysaccharide conjugate vaccines The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like, as well as antibodies ... | 02/26/2002 |
| 6326179 | Catalytic antibodies and a method of producing same The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mi... | 12/04/2001 |
| 6231852 | Method for reducing BCL-2 expressing cells resistance to death Methods for controlling cell death when the cell is exposed to one or more potentially lethal cellular insults. In one method, cell death is inhibited by introducing a reactive oxygen species limiter into the cell which prevents the build up of lethal lev... | 05/15/2001 |
| 6232082 | Hapten-carrier conjugates for treating and preventing nicotine addiction Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the ... | 05/15/2001 |
| 6228362 | Boron neutron capture therapy using pre-targeting methods The present invention provides a method for targeting boron atoms to tumor cells in a patient. The method includes the steps of (A) administering a targeting composition comprising a conjugate of (i) at least one first antibody or antigen-binding antibody... | 05/08/2001 |
| 6103233 | Cellular and serum protein anchors and conjugates First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an ... | 08/15/2000 |
| 5900237 | Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies Described and claimed are compounds of formula (I) wherein Y is a polypeptide, R1 is bonded to the N-terminus of Y and is hydrogen or a branched or linear, substituted or unsubstituted, C1-21 alkyl, alkene, or alkyne group, R2 | 05/04/1999 |
| 5876727 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition... | 03/02/1999 |
